
    
      Multicentre Early Access Programme, designed to provide treatment access to moxetumomab
      pasudotox for eligible patients with relapsed/refractory hairy cell leukemia who are at least
      18 years of age, have adequate organ function and are Pseudomonas-immunotoxin na√Øve. Patients
      will be administered moxetumomab pasudotox on Days 1, 3 and 5 of each 28-day cycle until
      documentation of CR or for up to 6 cycles, progressive disease (PD), initiation of alternate
      therapy or unacceptable toxicity.
    
  